List view / Grid view
Chemical synthesis of guide RNAs for CRISPR-Cas9 gene editing enables accurate and rapid production of CRISPR libraries and screening in an arrayed, one-gene-per-well fashion.
In this application note, discover how pools of synthetic crRNAs can produce a phenotype as strong as, or stronger, than any one of the component crRNAs in arrayed CRISPR screening experiments.
Horizon Discovery have developed their 3D OncoSignature™ spheroid screening service that consists of a panel of 200 cell lines. In this application note they demonstrate the ability of parallel 2D and 3D OncoSignature primary screens to identify known compounds with enhanced activity under 3D conditions.
Sign up for free weekly 5-10 min videos from Horizon’s expert cell line engineers to help you improve your CRISPR editing experiments.
This webinar explains how synthetic guide RNAs are stable, eliminate cloning and sequencing steps, and avoid innate immune responses and cytotoxicity.
The clinical success rate of new oncology drugs is low compared to other diseases. One contributing factor is likely to be the testing systems used, particularly two-dimensional (2D) monolayer assay formats, which are the traditional mainstay of high-throughput compound screening.
Horizon article on the recipe for success for CRISPR editing in T cells.
This article explains how to plan a gene-editing experiment. How to choose your biological system and what reagents to get for your experimental aim.
Modify the genome and modulate expression of genes within human iPS cells with Dharmacon™ Edit-R CRISPR reagents.
The identification and validation of novel drug targets is a challenging process for drug discovery programmes.
CRISPR screening utilises the power and precision of CRISPR-Cas9 gene editing to reveal and validate novel drug targets or to study the underlying causes of disease.
